Literature DB >> 23804632

Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses.

Daniel A Donahue1, Sophie M Bastarache, Richard D Sloan, Mark A Wainberg.   

Abstract

The HIV-1 latent reservoir represents an important source of genetic diversity that could contribute to viral evolution and multidrug resistance following latent virus reactivation. This could occur by superinfection of a latently infected cell. We asked whether latent viruses might be reactivated when their host cells are superinfected, and if so, whether they could contribute to the generation of recombinant viruses. Using populations of latently infected Jurkat cells, we found that latent viruses were efficiently reactivated upon superinfection. Pathways leading to latent virus reactivation via superinfection might include gp120-CD4/CXCR4-induced signaling, modulation of the cellular environment by Nef, and/or the activity of Tat produced upon superinfection. Using a range of antiviral compounds and genetic approaches, we show that gp120 and Nef are not required for latent virus reactivation by superinfection, but this process depends on production of functional Tat by the superinfecting virus. In a primary cell model of latency in unstimulated CD4 T cells, superinfection also led to latent virus reactivation. Drug-resistant latent viruses were also reactivated following superinfection in Jurkat cells and were able to undergo recombination with the superinfecting virus. Under drug-selective pressure, this generated multidrug-resistant recombinants that were identified by unique restriction digestion band patterns and by population-level sequencing. During conditions of poor drug adherence, treatment interruption or treatment failure, or in drug-impermeable sanctuary sites, reactivation of latent viruses by superinfection or other means could provide for the emergence or spread of replicatively fit viruses in the face of strong selective pressures.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23804632      PMCID: PMC3754111          DOI: 10.1128/JVI.01165-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  94 in total

1.  A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children.

Authors:  D Persaud; T Pierson; C Ruff; D Finzi; K R Chadwick; J B Margolick; A Ruff; N Hutton; S Ray; R F Siliciano
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  HIV-1 actively replicates in naive CD4(+) T cells residing within human lymphoid tissues.

Authors:  D A Eckstein; M L Penn; Y D Korin; D D Scripture-Adams; J A Zack; J F Kreisberg; M Roederer; M P Sherman; P S Chin; M A Goldsmith
Journal:  Immunity       Date:  2001-10       Impact factor: 31.745

3.  HIV envelope induces a cascade of cell signals in non-proliferating target cells that favor virus replication.

Authors:  Claudia Cicala; James Arthos; Sara M Selig; Glynn Dennis; Douglas A Hosack; Donald Van Ryk; Marion L Spangler; Tavis D Steenbeke; Prateeti Khazanie; Neil Gupta; Jun Yang; Marybeth Daucher; Richard A Lempicki; Anthony S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-27       Impact factor: 11.205

4.  Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.

Authors:  Neelanjana Ray; Jessamina E Harrison; Leslie A Blackburn; Jeffrey N Martin; Steven G Deeks; Robert W Doms
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

5.  Multiple proviral integration events after virological synapse-mediated HIV-1 spread.

Authors:  Rebecca A Russell; Nicola Martin; Ivonne Mitar; Emma Jones; Quentin J Sattentau
Journal:  Virology       Date:  2013-05-28       Impact factor: 3.616

Review 6.  HIV reservoirs: pathogenesis and obstacles to viral eradication and cure.

Authors:  Tae-Wook Chun; Anthony S Fauci
Journal:  AIDS       Date:  2012-06-19       Impact factor: 4.177

7.  Soluble HIV-1 gp120 enhances HIV-1 replication in non-dividing CD4+ T cells, mediated via cell signaling and Tat cofactor overexpression.

Authors:  Dorothée Missé; Johanna Gajardo; Christelle Oblet; Agniezska Religa; Nathalie Riquet; Danièle Mathieu; Hans Yssel; Francisco Veas
Journal:  AIDS       Date:  2005-06-10       Impact factor: 4.177

8.  HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

Authors:  Maria J Buzón; Marta Massanella; Josep M Llibre; Anna Esteve; Viktor Dahl; Maria C Puertas; Josep M Gatell; Pere Domingo; Roger Paredes; Mark Sharkey; Sarah Palmer; Mario Stevenson; Bonaventura Clotet; Julià Blanco; Javier Martinez-Picado
Journal:  Nat Med       Date:  2010-03-14       Impact factor: 53.440

9.  Deep molecular characterization of HIV-1 dynamics under suppressive HAART.

Authors:  Maria J Buzón; Francisco M Codoñer; Simon D W Frost; Christian Pou; Maria C Puertas; Marta Massanella; Judith Dalmau; Josep M Llibre; Mario Stevenson; Julià Blanco; Bonaventura Clotet; Roger Paredes; Javier Martinez-Picado
Journal:  PLoS Pathog       Date:  2011-10-27       Impact factor: 6.823

10.  Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells.

Authors:  Suha Saleh; Fiona Wightman; Saumya Ramanayake; Marina Alexander; Nitasha Kumar; Gabriela Khoury; Cândida Pereira; Damian Purcell; Paul U Cameron; Sharon R Lewin
Journal:  Retrovirology       Date:  2011-10-12       Impact factor: 4.602

View more
  12 in total

1.  Long Noncoding RNA uc002yug.2 Activates HIV-1 Latency through Regulation of mRNA Levels of Various RUNX1 Isoforms and Increased Tat Expression.

Authors:  Chen Huan; Zhaolong Li; Shanshan Ning; Hong Wang; Xiao-Fang Yu; Wenyan Zhang
Journal:  J Virol       Date:  2018-04-13       Impact factor: 5.103

Review 2.  HIV-1 Tat and Viral Latency: What We Can Learn from Naturally Occurring Sequence Variations.

Authors:  Doreen Kamori; Takamasa Ueno
Journal:  Front Microbiol       Date:  2017-01-30       Impact factor: 5.640

3.  Pyroptosis, superinfection, and the maintenance of the latent reservoir in HIV-1 infection.

Authors:  Dominik Wodarz; David N Levy
Journal:  Sci Rep       Date:  2017-06-19       Impact factor: 4.379

4.  Number of infection events per cell during HIV-1 cell-free infection.

Authors:  Yusuke Ito; Azaria Remion; Alexandra Tauzin; Keisuke Ejima; Shinji Nakaoka; Yoh Iwasa; Shingo Iwami; Fabrizio Mammano
Journal:  Sci Rep       Date:  2017-07-26       Impact factor: 4.379

5.  Persistence of Human Immunodeficiency Virus-1 Drug Resistance Mutations in Proviral Deoxyribonucleic Acid After Virologic Failure of Efavirenz-Containing Antiretroviral Regimens.

Authors:  Justin De La Cruz; Saran Vardhanbhuti; Malaya K Sahoo; Robert Rovner; Ronald J Bosch; Justen Manasa; David A Katzenstein; Benjamin A Pinsky
Journal:  Open Forum Infect Dis       Date:  2019-01-16       Impact factor: 3.835

6.  HIV-1-Specific Immunodominant T-Cell Responses Drive the Dynamics of HIV-1 Recombination Following Superinfection.

Authors:  Hui Zhang; Shuang Cao; Yang Gao; Xiao Sun; Fanming Jiang; Bin Zhao; Haibo Ding; Tao Dong; Xiaoxu Han; Hong Shang
Journal:  Front Immunol       Date:  2022-01-14       Impact factor: 7.561

Review 7.  Vitamin D receptor and epigenetics in HIV infection and drug abuse.

Authors:  Nirupama Chandel; Ashwani Malhotra; Pravin C Singhal
Journal:  Front Microbiol       Date:  2015-08-19       Impact factor: 5.640

8.  Fitness impaired drug resistant HIV-1 is not compromised in cell-to-cell transmission or establishment of and reactivation from latency.

Authors:  Sophie M Bastarache; Thibault Mesplède; Daniel A Donahue; Richard D Sloan; Mark A Wainberg
Journal:  Viruses       Date:  2014-09-19       Impact factor: 5.048

9.  Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses.

Authors:  Hanh T Pham; Thibault Mesplède; Mark A Wainberg
Journal:  Retrovirology       Date:  2016-04-30       Impact factor: 4.602

Review 10.  Prospecting for an HIV vaccine.

Authors:  D M Brett-Major; T A Crowell; N L Michael
Journal:  Trop Dis Travel Med Vaccines       Date:  2017-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.